Blood irradiators used to prevent cancer metastasis in the blood may need to be regulated under the US Food and Drug Administration’s highest-risk class III due to limited information, an agency advisory panel concluded at its 7 November meeting.
The radiologic devices advisory panel convened to make recommendations on the categorization of “blood irradiator devices intended to be used for the irradiation of intra-operatively salvaged blood for cancer patients...